The Longevity Science Foundation has launched a new call for funding for psychedelic research

LSF joins PsyMed Ventures in providing grants for projects exploring the synergy between psychedelics and longevity.

november 4, 2022 – Miami — The Longevity Science Foundation, a nonprofit organization dedicated to funding research establishing longer and healthier human lives, announced a new call for funding for psychedelic research during today’s event at Miami Wonderland. The funding call is a joint effort between the Longevity Science Foundation and PsyMed Ventures, an early-stage fund investing in frontier mental health technologies.

Although not usually discussed as such, mental and brain health are crucial components of human longevity. Psychedelic applications for mental health treatment are accelerating rapidly, with compounds such as ketamine, MDMA, and psilocybin showing promise in treating PTSD, depression, and addiction. Researchers have also shown that ketamine and psilocybin can help repair neural connections, a potentially groundbreaking finding in the development of future treatments for neurodegenerative diseases associated with aging.

The call for funding invites anyone at the forefront of the cutting-edge fields of longevity and psychedelic to submit grant-funded proposals. LSF and PsyMed specifically encourage applications from researchers working on projects related to the use of existing or new psychedelics to manage, delay or reverse age-related mental and brain diseases. They are also enthusiastic about proposals regarding the mechanisms behind the complex effects induced by psychedelic compounds and any other breakthrough areas that synergize the fields of longevity and psychedelics.

“Mental health is a vital but often overlooked aspect of longevity – I believe a healthy mind is just as important as a healthy body,” said Gary Zmudze, executive coordinator of the Longevity Science Foundation. “By funding research on psychedelics, the Longevity Science Foundation is contributing to a body of knowledge transforming brain health and longevity.”

“There has been incredible innovation in the development of psychedelic treatments for mental health,” said Lisa Ireland, president and CEO of the Longevity Science Foundation. “We are proud to announce this call for funding to support visionaries and researchers dedicated to expanding our understanding of psychedelics. We encourage others to learn more about this developing field.”

“PsyMed has been active in the psychedelic space for several years, partnering with over 13 companies in the field,” said Matthias Serebrinski, co-founder and general partner at PsyMed Ventures. “We are excited to work with LSF to explore new applications of these life-changing compounds and their benefits for human longevity.”

Applications for this funding call are being accepted continuously until April 30, 2023. To apply, visit

Tap Contact

Rachel Pippan, +31 06 422 13615, [email protected]

About the Longevity Science Foundation

The Longevity Science Foundation is a non-profit organization that promotes human longevity by funding research and development of medical technologies to extend people’s life spans. The Longevity Science Foundation’s long-term mission is to help make longevity care accessible to everyone, regardless of their background, by bringing cutting-edge aging science out of the lab and into the mainstream. To learn more, visit

About PsyMed Ventures

PsyMed Ventures is an early stage fund investing in psychedelic medicine and frontier mental health technologies. The community-focused fund provides capital and support to the best and most innovative companies that combine healing, responsibility and profitability. His investment focus covers psychedelics and novel compounds, neurotechnology and brain-computer interfaces, precision psychiatry and digital therapy. To learn more, visit

This post is sponsored. Cointelegraph does not endorse and is not responsible for the content, accuracy, quality, advertising, products or other materials on this page. Readers should do their own research before taking any action related to the company. Cointelegraph shall not be liable, directly or indirectly, for any damages or losses caused or alleged to be caused by or in connection with the use or reliance on any content, goods or services mentioned in the press release.

Leave a Comment